Diagnosis and Treatment of Superior Sagittal Sinus Thrombosis by Nasrazadani, David & Jensen, Robert
Kansas Journal of Medicine 2015  Superior Sagittal Sinus Thrombosis 
 
153 
 
 
 
 
 
 
 
Diagnosis and Treatment of 
Superior Sagittal Sinus Thrombosis 
David Nasrazadani, MS-41 
Robert Jensen, M.D., J.D.1,2 
1University of Kansas School of Medicine-
Wichita 
2Department of Internal Medicine
 
Introduction 
Cerebral venous sinus thrombosis 
(CVST), although a common diagnosis, is 
missed frequently by both general 
practitioners and neurologists.1 The most 
common presenting complaints are headache 
with focal neurological symptoms such as 
weakness, numbness, and aphasia.2 CVST 
has a female predominance of 3:1.3 A risk 
factor usually is able to be determined, most 
common of which is oral contraceptive 
use.4,5 Other prothrombotic risk factors 
include antithrombin III deficiency, 
dehydration, factor V Leiden mutation, 
increased factor VIII, infection, protein C 
and S deficiency, pregnancy, prothrombin 
mutation, malignancy, and trauma.2,6 The 
superior sagittal sinus is the most common 
site of cerebral venous thrombosis, followed 
by the other sinus systems.7-10 Treatment of 
CVST includes anticoagulation or 
thrombolytics with symptomatic support, 
although treatment with heparin has been 
controversial with some physicians hesitant 
to administer it due to the risk of 
hemorrhagic infarction.2,11 We report the 
diagnosis and treatment of superior sagittal 
sinus thrombosis.  
 
Case Report 
A 44-year-old, gravida 2, para 2, right-
handed, Caucasian female presented to the 
emergency department with acute symptoms 
of right leg, right arm, and right hand 
numbness and paresthesia. Additionally, she 
had difficulty moving her right leg which 
made it hard to walk. When she could no 
longer stand due to right leg weakness, she 
was taken to the emergency department. The 
MRI performed at this hospital showed 
diffusion restriction in the right parietal 
cortex. Additionally, there was a well 
demarcated fluid signal abnormality in the 
right dorsal medulla and the caudal aspect of 
the inferior cerebral peduncle. Rostral to 
this, there were bilateral circinate areas of 
fluid signal abnormality. Suspecting an 
acute stroke, she was transferred to our 
facility.  
The patient reported a history of 
progressive dysmotility of the right hand 
extending over the course of five years. Fine 
motor skills had degenerated to the point 
that the patient began to write with her non-
dominant left hand. While doing this, she 
noted tremor-like associated movements of 
the right hand. Medications included 
atorvastatin, escitalopram, omeprazole, and 
trazodone. She had taken oral contraceptives 
in the past, but stopped approximately five 
years prior. 
Physical exam showed reduced facial 
sensation in the ophthalmic, maxillary, and 
mandibular branches of the trigeminal nerve 
on the right. The patient had a modest right 
hemiparesis and dysmotility and a moderate 
ataxia in the right arm and leg. Stereognosis 
was reduced on the right. The patient could 
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not stand due to right leg weakness. Pupils 
were round and reactive to light bilaterally 
with extra ocular eye movements intact and 
no photophobia. She did not have nuchal 
rigidity. Palatal arch elevated symmetrically. 
Reflexes were normal and symmetric 
bilaterally.  
An ultrasound carotid duplex study 
showed minimal atherosclerotic disease 
involving both carotid systems, but no 
evidence for a hemodynamically significant 
stenosis of the common or internal carotid 
arteries. An echocardiogram bubble study 
showed normal left ventricular systolic 
function and wall motion with ejection 
fraction estimated at 55 to 60% and no 
evidence of right-to-left shunting. MRI of 
the cervical spine showed no evidence for 
spinal stenosis or nerve root encroachment, 
but there were several sub-centimeter 
nodules associated with the thyroid gland. 
Magnetic resonance arteriogram (MRA) of 
the brain without contrast showed no 
evidence of an aneurysm of the circle of 
Willis and there was no hemodynamically 
significant stenosis identified. MRI of the 
brain with and without contrast showed a 
new para-Rolandic central and parietal high 
convexity cortical signal abnormality in 
addition to the signal abnormality seen on 
the right parietal cortex on previous 
imaging. Abnormal signal in the right 
inferior cerebellar peduncle and left dorsal 
medulla also were seen, as well as a sulcal 
tendril of abnormal signal flowing down 
from a high convexity cortical or meningeal 
level, indicating a possible subarachnoid 
bleed (Figure 1). She was admitted for 
further workup of the etiology of her 
symptoms. 
 
 
 
 
 
 
Figure 1. Coronal T1W MRI demonstrates small 
foci of abnormal hyperintense signal 
demonstrated within the dorsal medulla 
(arrows). 
 
On day two post-admission, she 
experienced new-onset numbness on the left 
side of her face and the palm of her left hand 
that was accompanied by ataxia of her left 
arm and uncontrollable head bobbing. This 
episode lasted for approximately one minute 
and was not apparent on physical exam. The 
patient reported being able to walk with 
minimal assistance but dragging of her right 
foot was observed. These symptoms raised 
concerns of a new neurologic process of 
unclear etiology, and an extensive workup 
for demyelinating disease, infectious 
disease, or thrombotic disease was 
undertaken. 
On day six, cerebral spinal fluid analysis 
showed 18 white cells (92% lymphocytes) 
and 253 red cells. Cerebrospinal fluid 
protein was 45 mg/dL and glucose 65 mg/dL 
(serum 113 mg/dL). No oligoclonal bands 
were detected. Cryptococcal antigen and 
VDRL titers were negative. Further 
infectious workup of Lyme disease, West 
Nile virus, and HIV were negative. 
Dexamethasone 2mg PO TID, divalproex 
sodium 500 mg PO BID, topiramate 25 mg 
PO daily, and minocycline 100 mg PO 
q12hr were started for the suspicion of a 
demyelinating process possibly contributing 
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to her symptoms. Thyroid ultrasound 
revealed multiple hypo-echoic lesions in 
each lobe which were interpreted as benign 
with a recommendation to repeat in six 
months. Thyroid stimulating hormone with 
reflex free T4 level was normal. Computed 
tomography (CT) of the chest and abdomen 
revealed a 4 mm right lower lobe pulmonary 
nodule with a recommendation to reimage in 
six months to assess stability. No 
abnormally enlarged lymph nodes in the 
chest, abdomen, or pelvis were found.  
Repeat MRI revealed a new abnormal 
high T1 signal intensity demonstrated 
throughout the superior sagittal sinus as well 
as some central low signal within the 
superior sagittal sinus on the gradient 
acquisition, suggestive of superior sagittal 
sinus thrombosis (Figure 2). FLAIR 
acquisition also demonstrated some 
nonspecific foci of high T2 signal 
demonstrated within the posterior aspect of 
the medulla. This appeared unchanged from 
previous imaging. Dexamethasone, 
divalproex sodium, topiramate, and 
minocycline were discontinued and 
anticoagulation started with heparin drip 18 
unit/kg/hr and warfarin 5 mg PO daily with 
a partial thromboplastin time (PTT) goal of 
at least 75 and an INR goal of 2-3.  
Seven days post-admission, the patient 
reported the abnormal movements of her 
right arm had improved. She was walking 
without assistance. She also denied 
symptoms of right leg or right arm 
weakness, but reported mild dizziness and 
another brief episode of left palm numbness 
that lasted approximately one minute. A 
coagulopathy workup was initiated in an 
attempt to determine the source of the 
thrombosis. Blood and urine homocysteine 
levels were normal. The patient was 
heterozygous for methylenetetrahydrofolate 
reductase (MTHFR) gene mutation and 
negative for prothrombin G20210A 
mutation. Coagulation studies indicated an 
elevated Factor VIII of 227 (normal 50-
150). Antithrombin, protein C and S, B6, 
folate and B12 levels were within normal 
ranges. 
 
Figure 2. Axial T1W MRI demonstrates 
thrombosis throughout the superior sagittal sinus 
(arrows). 
 
Eleven days after admission, the patient 
denied right leg or right arm numbness with 
no ataxia of her right limb. She was able to 
walk normally without assistance and denied 
dizziness or weakness. Routine CT scan of 
the brain revealed no intracranial 
hemorrhage as a result of heparin and 
warfarin treatment. At that time, her PTT 
was 91.7 and INR 1.7. Her warfarin dose 
was increased to 7.5 mg PO daily and 
heparin drip adjusted to 22.5 mL/hour. 
Urinalysis was negative for white cells, red 
cells, leukocyte esterase, glucose, or protein. 
Blood cultures were negative for bacterial or 
fungal growth.  
On the sixteenth and final day of 
hospitalization, the patient had no symptoms 
of weakness, numbness, paresthesia, 
dizziness, or difficulty walking. On 
discharge, her INR was 2.1 and PTT 99.3. 
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Heparin was discontinued and the patient 
continued on 7.5 mg warfarin PO daily, with 
a follow up appointment scheduled in the 
outpatient clinic and repeat MRI to assess 
treatment.  
 
Discussion 
Although a common diagnosis, cerebral 
venous sinus thrombosis (CVST) is missed 
frequently by both neurologists and general 
practicitioners.1 The most common 
symptom is headache (70%), followed by 
focal neurologic signs such as aphasia, 
numbness, and weakness (29%).2 A study 
that included 625 patients from 89 centers in 
Europe with CVST found the mean age of 
patients was 39.1 years with a 3:1 female 
predominance.3 In most diagnoses of CVST, 
there is usually a prothrombotic risk factor 
that is likely the etiology that predisposes to 
CVST, most commonly oral contraceptive 
use. Some studies calculate a >10-fold 
increase in the risk of thrombotic events in 
women taking oral contraceptives.4,5 Other 
prothrombotic risk factors include 
antithrombin III deficiency, dehydration, 
factor V Leiden mutation, increased factor 
VIII, infection, protein C and S deficiency, 
pregnancy, prothrombin mutation, 
malignancy, and trauma.2,6 
Hyperhomocysteinemia has been 
suggested as a risk factor for deep vein 
thrombosis and stroke, but has not been 
shown to cause increased risk for CVST.7 
The heterozygous mutation of the MTHFR 
gene is not an independent risk factor for 
CVST; however, this patient’s combined 
risk factors of elevated factor VIII, previous 
exposure to oral contraceptives, and prior 
pregnancies may be compounded further by 
heterozygosity of the MTHFR gene.12 The 
superior sagittal sinus is the most common 
site of cerebral venous thrombosis. Other 
sinus systems can be affected, including the 
sigmoid and transverse sinuses.7-10  
Imaging of the brain is necessary to 
diagnose CVST.13 Non-contrast computed 
tomography (CT) usually is performed in the 
emergency department when a central 
neurologic process is suspected. The most 
common findings in CVST using this 
method are hyperdense foci or generalized 
swelling.14 However, a normal CT scan or 
MRI does not exclude the diagnosis of 
CVST. In a study where 52 patients had 
evidence of CVST, 9 of the 30 patients who 
had a CT as the first imaging study had 
normal findings. Of these nine, the MRIs of 
four of the patients were also normal. Using 
an MR venogram (MRV) study, evidence of 
CVST was revealed in two of the four 
patients. The authors of this study concluded 
that MRV is the investigation of choice for 
confirming CVST.1 
Treatment for CVST includes initial 
anticoagulation with heparin or 
thrombolytics, with symptomatic therapy.11 
The use of heparin has come into question 
because of its association with hemorrhagic 
infarction in up to 40% of CVST cases.2 For 
this reason, physicians hesitate to administer 
heparin. Unfortunately, there are few 
controlled trials on the safety and efficacy of 
anticoagulation treatment for CVST. A 
meta-analysis of two small trials of 80 
patients which compared the safety and 
efficacy of anticoagulation with placebo 
showed that the use of anticoagulation had 
an absolute risk reduction in death or 
dependency of 13% (confidence interval -30 
to +3%) with a relative risk reduction of 
54%.15 Intracranial hemorrhage has not been 
shown to be a contraindication to 
anticoagulation when related to CVST.11 It 
is unclear if low molecular weight heparin 
(LMWH) is a better choice than dose-
adjusted intravenous heparin, or vice versa. 
LMWH given subcutaneously increases the 
mobility of patients and reduces the need for 
laboratory monitoring and dose adjustments. 
However, intravenous heparin can be 
discontinued and an activated partial 
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thromboplastin time normalized within one 
to two hours if complications occur.  
Thrombolytic therapy for the treatment 
of CVST is an option.16 Thrombolytic 
therapy with tissue plasminogen activator 
(tPA) after failed anticoagulation was an 
effective treatment in patients with severe or 
worsening CVST. Those who had 
thrombolytic treatment after worsening of 
symptoms survived with mild residual 
neurologic damage or symptom-free 
recovery. The same study also found that 
patients who had only mild symptoms or no 
worsening of clinical course benefited from 
anticoagulation therapy alone. 
Other studies of thrombolytic therapy for 
the treatment of CVST have seen similar 
results, with rapid and complete 
recanalization achieved with full recovery. 
However, there were two extra-cerebral 
bleeding events and two patients whose pre-
treatment intracranial hemorrhage 
worsened.17,18 There may be a higher risk of 
bleeding complications with thrombolytic 
treatment compared to anticoagulation 
therapy, particularly in patients with 
intracranial hemorrhage before treatment.19 
Oral anticoagulation for three months 
with a target international normalized ratio 
(INR) of 2.0-3.0 has been recommended if 
CVST is believed to be secondary to a 
reversible risk factor such as oral 
contraceptive use, infection, or dehydration. 
If idiopathic, oral anticoagulation is 
recommended for 6-12 months.20 Oral 
anticoagulation for 6-12 months is 
recommended for patients with a mild 
hereditary thrombophilia such as 
prothrombin G202A mutation, heterozygous 
factor V Leiden mutation, or protein C or S 
deficiency. More severe cases of hereditary 
coagulopathies with frequent recurrences 
such as antithrombin deficiency or 
homozygous factor V Leiden mutation may 
require oral anticoagulation indefinitely. The 
clinician’s judgment in the severity of the 
hereditary thrombophilia, if present, may 
decide the length of treatment. Our patient 
had identifiable risk factors for CVST which 
may warrant long-term treatment with oral 
anticoagulation and scrupulous monitoring 
for potentially fatal side effects of treatment.  
The etiology of the patient’s new 
neurologic symptoms on day 2 post-
admission remained unclear. The small foci 
of the abnormal hyper-intense signal 
demonstrated within the dorsal medulla 
were present even when the symptoms 
resolved. Workup did not reveal a cause for 
these lesions and the patient had become 
asymptomatic. As such, follow-up to the 
neurology clinic as an outpatient was 
recommended to monitor the lesions for any 
changes. 
While common, CVST is a frequently 
missed diagnosis. Its symptoms can present 
similarly to an acute stroke and should be 
suspected in patient populations where acute 
strokes are uncommon. The superior sagittal 
sinus is the most common site of dural sinus 
thrombosis, and the gold standard for 
diagnosis is MRV. Treatment is 
controversial but intravenous heparin 
administration with bridging to oral 
anticoagulation is used most commonly. 
More studies are needed to determine the 
safest and most efficacious treatment for 
CVST. 
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